Immuron booms on Travelan’s positive research result

Drug developer Immuron’s Travelan anti-diarrhoea oral antibody product set the company share price alight this morning following positive news from clinical trials in the United States.

Travelan, which is made in Melbourne and on sale through Chemist Warehouse, is a non-absorbable, safe product which is composed of anti-bacterial antibodies that boost the gut immune system.

Trials funded by the US Department of Defense showed a 36.4 protective efficacy against Enterotoxigenic Escherichia coli (ETEC) caused moderate to severe diarrhea compared to a placebo group.

Travelan showed a 66.7 percent efficacy against ETEC caused severe diarrhea.

By mid-morning Immuron’s shares were trading at 11 cents, up 66.67 percent on the previous night’s closing price.

The US Department of Defense has been considering the use of Travelan by personnel deployed around the world where Campylobacter and Enterotoxigenic Escherichia coli infection is common and debilitating.

Immuron told investors: “The company will now proceed to hold an end point of Phase 2 meeting with the US Food and Drug Administration to discuss (its) pivotal Phase 3 registration strategy and planned clinical trials including recommended dosing to support a Biologics License Application for Travelan as a prophylactic medicine for Travelers Diarrhea.

“A preventative treatment that defence against infectious enteric diseases is a high priority objective for the US Military.”

The study results released were for 60 subjects who were treated with Travelan and later exposed to ETEC. Treatment continued for seven days.

The results showed a 83.3 percent reduction in the number of subjects taking Travelan requiring early antibiotic treatment.

Additionally, 100 percent of the subjects requiring IV fluids were in the placebo ir untreated group.

Picture: Immuron